It’s been a crucial week for Evoke Pharma, Inc. (NASDAQ:EVOK); here’s what analysts have to say.

October 2, 2018 - By Hugh Holland

Evoke Pharma, Inc. (NASDAQ:EVOK) LogoInvestors sentiment increased to 1.67 in Q2 2018. Its up 1.34, from 0.33 in 2018Q1. It is positive, as 3 investors sold Evoke Pharma, Inc. shares while 0 reduced holdings. 2 funds opened positions while 3 raised stakes. 3.11 million shares or 38.17% more from 2.25 million shares in 2018Q1 were reported.
Knoll L P holds 275,000 shares. 36,700 were accumulated by California Employees Retirement System. Moreover, Morgan Stanley has 0% invested in Evoke Pharma, Inc. (NASDAQ:EVOK). Blackrock invested in 76,288 shares or 0% of the stock. Citigroup reported 500 shares. Vanguard Grp Inc invested in 0% or 536,541 shares. Two Sigma Secs Ltd Com reported 18,825 shares. United Capital Finance Advisers reported 15,566 shares stake. Northern Trust, a Illinois-based fund reported 33,997 shares. 683 Capital Mgmt Limited Liability Corp invested in 0.02% or 114,300 shares. Creative Planning holds 0% or 100,000 shares. Geode Cap Management Limited Co owns 23,048 shares or 0% of their US portfolio. Sphera Funds owns 1.41M shares for 0.49% of their portfolio. Bancorporation Of New York Mellon has 0% invested in Evoke Pharma, Inc. (NASDAQ:EVOK) for 24,908 shares. State Treasurer State Of Michigan holds 0.01% or 400,000 shares in its portfolio.

Since August 20, 2018, it had 1 buying transaction, and 0 insider sales for $1.18 million activity.

Evoke Pharma, Inc. (NASDAQ:EVOK) Ratings Coverage

Among 2 analysts covering Evoke Pharma (NASDAQ:EVOK), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Evoke Pharma had 3 analyst reports since May 3, 2018 according to SRatingsIntel. H.C. Wainwright maintained Evoke Pharma, Inc. (NASDAQ:EVOK) rating on Tuesday, June 5. H.C. Wainwright has “Buy” rating and $900 target. FBR Capital maintained Evoke Pharma, Inc. (NASDAQ:EVOK) on Tuesday, June 5 with “Buy” rating. H.C. Wainwright maintained Evoke Pharma, Inc. (NASDAQ:EVOK) on Thursday, May 3 with “Buy” rating. Below is a list of Evoke Pharma, Inc. (NASDAQ:EVOK) latest ratings and price target changes.

05/06/2018 Broker: FBR Capital Rating: Buy New Target: $5.0000 Maintain
05/06/2018 Broker: H.C. Wainwright Rating: Buy New Target: $9.0000 Maintain
03/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $9.0000 Maintain

The stock increased 0.67% or $0.02 during the last trading session, reaching $3.02. About 50,764 shares traded. Evoke Pharma, Inc. (NASDAQ:EVOK) has risen 7.80% since October 2, 2017 and is uptrending. It has underperformed by 7.82% the S&P500.

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. The company has market cap of $51.03 million. It is developing Gimoti, a metoclopramide nasal spray, which completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. It currently has negative earnings.

Evoke Pharma, Inc. (NASDAQ:EVOK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>